Related Experiment Video
Updated: May 10, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Panitumumab in metastatic colorectal cancer
Christopher M Hocking1, Amanda R Townsend, Timothy J Price
1Department of Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia.
Abstract:
Increasing chemotherapeutic and targeted drug options has led to improved overall survival in metastatic colorectal cancer. Panitumumab is a fully humanized monoclonal antibody that binds to the EGF receptor and inhibits downstream cell signaling with net effects of inhibition of tumor growth, induction of apoptosis and inhibition of angiogenesis. Panitumumab leads to improved response rate and progression-free survival when used in combination with chemotherapy and as monotherapy in metastatic colorectal cancer. This benefit is limited to patients who have non-mutated KRAS tumors, and regulatory agencies worldwide have restricted panitumumab to this patient population. Rash is a common side effect of panitumumab, and prophylactic skin treatments are advised. The optimal use of panitumumab is evolving and will become further defined with results of upcoming clinical trials and improved identification of biomarkers predicting benefit of this class of drugs.
Insights
Panitumumab improves survival in metastatic colorectal cancer for patients with non-mutated KRAS tumors. This targeted therapy shows benefits in response rate and progression-free survival.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Metastatic colorectal cancer (mCRC) treatment has advanced with new chemotherapeutic and targeted drug options, improving overall survival.
- Panitumumab, a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), inhibits tumor growth, promotes apoptosis, and reduces angiogenesis.
- Clinical evidence supports panitumumab's efficacy in improving response rates and progression-free survival for mCRC patients.
Purpose of the Study:
- To review the efficacy and optimal use of panitumumab in metastatic colorectal cancer.
- To highlight the importance of KRAS mutation status in predicting panitumumab benefit.
- To discuss the side effect profile and future directions for panitumumab therapy.
Main Methods:
- Review of clinical trial data and regulatory guidelines regarding panitumumab use in mCRC.
- Analysis of panitumumab's mechanism of action, including EGFR inhibition and downstream signaling.
- Evaluation of patient populations benefiting from panitumumab, specifically those with non-mutated KRAS tumors.
Main Results:
- Panitumumab demonstrates improved response rate and progression-free survival in mCRC when used with chemotherapy or alone.
- The therapeutic benefit of panitumumab is restricted to patients with KRAS wild-type (non-mutated) tumors.
- Skin rash is a frequent adverse event associated with panitumumab, necessitating prophylactic management.
Conclusions:
- Panitumumab is an effective targeted therapy for a subset of metastatic colorectal cancer patients with non-mutated KRAS tumors.
- Biomarker identification, particularly KRAS status, is crucial for selecting appropriate patients for panitumumab treatment.
- Ongoing research and clinical trials are essential to further define the optimal use and expand the benefits of panitumumab and similar EGFR-targeting agents.
